Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations
Egle Avizienyte(Cancer Research UK Scotland Institute), Andrew P. Garner(AstraZeneca (United Kingdom))
Cited by 89